Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Participants With High Red Blood Cell Transfusion Burden
NCT07722988 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Participants With High Red Blood Cell Transfusion Burden
- Lead sponsor
- Kyntra Bio
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- April 30, 2027
- Completion date
- December 31, 2032
- Enrollment
- 201 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.